Physician profile
David L Pyle
NPI 1730118167
$92,515.03
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,948 · 2020: $2,039 · 2021: $2,657 · 2022: $25K · 2023: $27K · 2024: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $57,566.20 |
| Food and Beverage | $2,126.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $80,070.50 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,472.88 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $1,314.26 | 2019-2023 | Otezla, Repatha, Prolia |
| Pfizer INC. | $1,090.07 | 2019-2023 | |
| Glaxosmithkline, LLC. | $995.86 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $810.78 | 2019-2022 | |
| Abbvie INC. | $683.95 | 2021-2023 | |
| Astellas Pharma US INC | $568.25 | 2019-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $499.08 | 2019-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $462.80 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.72 | 2019-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.89 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $417.85 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $414.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $357.15 | 2019-2023 | Verquvo, Belsomra |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.